Book a Meeting

Non-fucosylated Anti-Human CD73 (Oleclumab) Therapeutic Antibody (CAT#: BioBet-402ZP) Datasheet

Target
CD73
Isotype
IgG1, λ
Description
ADCC-enhanced Oleclumab is a non-fucosylated anti-CD73 therapeutic biobetter antibody.
Indication
Solid Tumours, Pancreatic and Colorectal cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD73 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
NT5E
Full Name
5'-Nucleotidase Ecto
Background
The protein encoded by this gene is a plasma membrane protein that catalyzes the conversion of extracellular nucleotides to membrane-permeable nucleosides. The encoded protein is used as a determinant of lymphocyte differentiation. Defects in this gene can lead to the calcification of joints and arteries. Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Mar 2011]
Alternative Names
NT; eN; NT5; NTE; eNT; CD73; E5NT; CALJA
Gene ID
4907
UniProt ID
P21589
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with NT5E include Calcification Of Joints And Arteries and Intestinal Tuberculosis.
Related Pathways
Its related pathways are Neuroscience and ATP/ITP metabolism.
Function
Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
Field of research
Cell Biology and Cellular Response antibody
Post-translational modifications
1.Glycosylation at Asn53, Asn311, Asn333, and Asn403. 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, λ
Antibody Clone
Oleclumab
Host
Human
Species Reactivity
Human
Description
ADCC-enhanced Oleclumab is a non-fucosylated anti-CD73 therapeutic biobetter antibody.
Indication
Solid Tumours, Pancreatic and Colorectal cancer

Solid Tumours, Pancreatic and Colorectal cancer

Related Products

Highly Galactosylated Anti-CD73 (Oleclumab) Antibody (CAT#: BioBet-GA-402ZP)
BetterBet™ Anti-CD73 Half-Life Extended Antibody (CAT#: AES-0622-ZP1301)
BetterBet™ Anti-CD73 On-Target Antibody (CAT#: AES-0622-ZP973)
BetterBet™ Anti-CD73 Recycling Antibody (CAT#: AES-0622-ZP317)
BetterBet™ Anti-CD73 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP645)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany